Glycemic Control Guidelines

Introduction to Glycemic Control

Glycemic control is crucial for preventing or delaying microvascular complications in patients with diabetes, as recommended by the KDOQI guidelines 1
The American College of Physicians and the American Diabetes Association provide guidelines for glycemic control, including target HbA1c levels and treatment considerations 2, 3, 4, 5

The American College of Physicians recommends a target HbA1c between 7.0-8.0% for most patients, while the KDOQI guidelines recommend a target HbA1c of 7.0% to prevent or delay microvascular complications 2, 1
For non-pregnant adults, the American Diabetes Association recommends an A1c target of <7.0%, with more stringent targets of <6.5% for selected patients and less stringent targets of <8.0% for patients with history of severe hypoglycemia or advanced complications 3, 4, 6, 7, 8
For patients of advanced age, an A1C target of 7.0-8.0% may be appropriate depending on comorbidities and hypoglycemia risk 2
The American College of Physicians recommends a long-term target of HbA1c <7.0% for most non-pregnant adults without significant comorbidities 5

For patients with high risk of hypoglycemia, consider adding DPP-4 inhibitor or α-glucosidase inhibitor, while for patients without specific comorbidities, consider adding sulfonylurea, thiazolidinedione, or other oral agent 6
For patients with CKD, avoid treating to an HbA1c target of <7.0% if at risk of hypoglycemia, and in patients with advanced CKD (stages 4-5), adjust medication dosages and be cautious with agents cleared by the kidneys 1
Insulin therapy should be initiated in patients with severely uncontrolled diabetes (A1c ≥10%) and type 1 diabetes, with multiple daily injections (MDI) of basal and prandial insulin, starting with approximately 0.1-0.2 units/kg per meal, and adjusted based on carbohydrate intake, pre-meal glucose, and anticipated activity, as recommended by the American Diabetes Association 9, 10, 11, 5
The American College of Physicians recommends starting with basal insulin (glargine, detemir, or degludec) once daily and adding prandial insulin before meals, with initial dosing of 0.5-0.6 units/kg/day total, divided approximately 50% as basal and 50% as prandial insulin 5

Consider a less stringent HbA1c target (7.5-8.0% or higher) for patients with limited life expectancy, advanced age, history of severe hypoglycemia, or advanced complications or comorbidities 2
For patients with prediabetes, consider referral to an intensive diet and physical activity behavioral counseling program targeting 7% weight loss and at least 150 minutes per week of moderate-intensity physical activity, as recommended by the American Diabetes Association 12
Metformin may be considered for patients with prediabetes, especially those with a BMI >35 kg/m², age <60 years, history of gestational diabetes, or more severe or progressive hyperglycemia, as suggested by the American Diabetes Association 12

When targeting lower HbA1c levels, always assess the risk of hypoglycemia, especially in patients with CKD, elderly patients, or those on insulin or sulfonylureas 1
The American Diabetes Association recommends asking about symptomatic and asymptomatic hypoglycemia at each encounter, to monitor for hypoglycemia 8
Clinical signals of overbasalization, such as elevated bedtime-to-morning glucose differential, hypoglycemia, or high glucose variability, should be watched for, as suggested by the American Diabetes Association 7, 13

Metformin is recommended as the preferred first-line pharmacologic agent for type 2 diabetes due to its efficacy, safety, low cost, and potential cardiovascular benefits, as recommended by the American College of Physicians 5
Metformin plus one of six treatment options, including sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or basal insulin, as first-line combination therapy for uncontrolled diabetes mellitus, with the specific choice based on patient characteristics, comorbidities, and glycemic targets 5
SGLT2 inhibitors or GLP-1 receptor agonists with proven CV benefit should be considered for patients with established atherosclerotic cardiovascular disease, and SGLT2 inhibitors should be preferred for patients with high risk for heart failure, as recommended by the American Heart Association and American College of Cardiology 14, 15, 13

Regular physical activity, aiming for 150 minutes of moderate-intensity activity per week, is recommended for patients with diabetes, as advised by the American Diabetes Association, American Heart Association, and Academy of Nutrition and Dietetics 16, 9, 15
A structured meal plan focusing on consistent carbohydrate intake with emphasis on complex carbohydrates, increased fiber intake, and reduced intake of refined carbohydrates and added sugars is recommended, according to the American Diabetes Association 17
Weight management is recommended for patients with BMI >25 kg/m², with a target of 5-10% weight loss, as suggested by the American Association of Clinical Endocrinologists and supported by the American Heart Association and Academy of Nutrition and Dietetics 18, 19, 20, 21, 14, 8, 10, 22, 7, 23

Addressing other cardiovascular risk factors, such as blood pressure and lipid management, is crucial for comprehensive diabetes care, with a blood pressure target of <140/90 mmHg (<130/80 mmHg for those with chronic kidney disease), and statin therapy should be considered based on cardiovascular risk, as recommended by the American Heart Association and American College of Cardiology 20, 3, 24

Delaying insulin therapy can worsen severe hyperglycemia, and immediate insulin therapy is required for blood sugar levels above a certain threshold, and it is crucial to always assess for signs of metabolic decompensation that would require emergency care, such as diabetic ketoacidosis or hyperosmolar hyperglycemic state 25, 26
Severe hyperglycemia may indicate intercurrent illness that requires additional management, and it is essential to assess for potential precipitating factors such as infection, medication non-adherence, dietary indiscretion, new medications, and stress or illness 25, 26